Completed PHASE2 INTERVENTIONAL 2-arm NCT01991028

A Study to Investigate Lung Deposition of Radiolabelled OligoG

An Open Label, Randomised, Two-way Crossover Scintigraphic Study to Investigate Lung Deposition of Radiolabelled OligoG Delivered as a Dry Powder and as a Nebulised Solution in Cystic Fibrosis Patients

Sponsor: AlgiPharma AS

Conditions Cystic Fibrosis

Interventions Radiolabelled OligoG CF-5/20 6% Solution Radiolabelled OligoG CF-5/20 DPI

Updated 6 times since 2017 Last updated: Feb 6, 2015 Started: Apr 30, 2014 Primary completion: Sep 30, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cystic Fibrosis and is currently completed. AlgiPharma AS leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2018 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Completed PHASE2

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AlgiPharma AS
BDD Pharma Ltd

Data source: BDD Pharma Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Glasgow, United Kingdom